22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
The first wave of discussion about the impact of COVID-19 on EU merger control was very much on the ...
Read More >
The market favors training that is interactive, scenario-based and topical. People also want complia...
Read More >
In terms of value, the technology and healthcare sectors—separately and, sometimes, in tandem—have...
Read More >
With our ever increasingly global workforce, it is becoming critical to have an awareness of immigra...
Read More >
After a number of controversial bills proposed from various industry groups over the last few years,...
Read More >
Saudi Aramco’s mega IPO plans are back on, and while valuation and other stumbling blocks remain, t...
Read More >